Around 630,000 people died from AIDS-related illnesses worldwide in 2024. That number, while still enormous, represents a 70% drop from the peak of 2.1 million deaths in 2004. The decline is almost entirely due to the global expansion of antiretroviral therapy, which has saved an estimated 26.9 million lives since it became available.
How Deaths Have Dropped Since the Peak
The worst year for AIDS mortality was 2004, when roughly 2.1 million people died. By 2010, that figure had fallen to 1.4 million, and by 2024 it reached 630,000. That trajectory reflects one of the most dramatic declines in infectious disease mortality in modern history, driven largely by a single intervention: getting antiretroviral drugs to the people who need them.
Between 1995 and 2015 alone, antiretroviral therapy averted an estimated 9.5 million deaths globally. If current scale-up efforts hit their targets, projections suggest a total of 34.9 million deaths could be averted between 1995 and 2030. The drugs don’t cure HIV, but they suppress the virus so effectively that a person on treatment can live a near-normal lifespan and never progress to AIDS.
Who Is Still Dying
The 630,000 annual deaths are not distributed evenly. Children and adolescents under 20 account for roughly 90,000 of those deaths, about 14% of the total. That works out to approximately 250 children dying from AIDS-related causes every day, mostly because they lack access to testing and treatment that adults in the same countries may already have.
Sub-Saharan Africa continues to carry the heaviest burden. The region has the largest number of people living with HIV and, despite major progress in treatment access, still accounts for a disproportionate share of global deaths. Gaps in diagnosis, drug supply, and healthcare infrastructure keep mortality higher in low-income settings than the biology of the disease demands.
What People Actually Die From
AIDS itself is not a single disease. It’s a state of immune collapse caused by untreated HIV, which leaves the body unable to fight infections and cancers it would normally control. The specific illnesses that kill people with AIDS vary, but a few dominate.
Tuberculosis is the single biggest killer. In 2024, about 150,000 people with HIV died from TB. The two diseases fuel each other: HIV weakens the immune defenses that keep latent TB in check, and TB accelerates HIV progression. Together, they remain one of the deadliest co-infections in global health.
Cancer is another major cause of death among people living with HIV, responsible for an estimated 30% of mortality in this population. Some of these cancers are directly linked to immune suppression, like certain lymphomas and Kaposi sarcoma. Others, including lung and liver cancers, occur at higher rates in people with HIV even when their virus is well controlled, likely because of chronic inflammation and higher rates of smoking and hepatitis co-infection.
Cardiovascular disease and other non-communicable diseases also play a growing role. A study in Uganda found that 11 to 30% of deaths among people with HIV were caused by non-communicable diseases, with heart disease leading the list. As antiretroviral therapy keeps people alive longer, these conditions are becoming a larger share of what ultimately kills them.
AIDS Deaths in the United States
In the U.S., AIDS-related mortality is far lower than the global average thanks to widespread treatment access. In 2023, there were 4,496 HIV-related deaths among people aged 13 and older with diagnosed HIV, a rate of 1.6 per 100,000. That number reflects both the effectiveness of treatment and the remaining gaps: late diagnosis, inconsistent medication use, and disparities in healthcare access that still cost thousands of Americans their lives each year.
Why 630,000 Deaths Are Still Happening
The global goal is to get 95% of people with HIV diagnosed, 95% of those diagnosed on treatment, and 95% of those on treatment virally suppressed. Progress toward those targets has been substantial but uneven. The people still dying fall into predictable categories: those who don’t know they have HIV, those who know but can’t access or stay on treatment, and those diagnosed too late for treatment to reverse the damage already done to their immune system.
Children are a particularly stark example. Pediatric HIV treatment requires different drug formulations and consistent follow-up care, both of which are harder to deliver in resource-limited settings. The result is that children make up a share of AIDS deaths far out of proportion to their share of total infections.
Geography matters enormously. A person diagnosed with HIV in a high-income country today has access to a single daily pill that can reduce the virus to undetectable levels within months. A person with the same diagnosis in a rural part of sub-Saharan Africa may face drug stockouts, clinic visits that require a full day of travel, and stigma that discourages testing in the first place. The virus is the same. The outcomes are not.